Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.

Autor:	Robertson D; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., Dixon C; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., Aungst A; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., McCoy B; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., Moreo N; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., Casady L; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA., Maldonado J; a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA.
Jazyk:	angličtina
Zdroj:	Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2017 Dec; Vol. 10 (12), pp. 1403-1407. Date of Electronic Publication: 2017 Nov 02.
DOI:	10.1080/17512433.2017.1395280
Abstrakt:	Background: Teriflunomide is an oral disease modifying therapy approved for the treatment of relapsing forms of multiple sclerosis. Teriflunomide' s pharmacokinetics (PK) contribute to its slow elimination, on average taking 6-8 months, though it can take up to 2 years in some instances. This slow elimination can become problematic in certain clinical situations - such as during pregnancy, when teriflunomide has potential teratogenic effects. In such scenarios, an accelerated elimination procedure (AEP) is recommended. Currently, AEPs with oral cholestyramine or activated charcoal are available but are restricted by adverse effects, limited administration routes, and dosing frequencies. Methods: A single-center, PK interaction study was performed in a total of 14 healthy volunteers, to investigate colestipol hydrochloride (HCl) as an alternative to cholestyramine for the elimination of teriflunomide. Participants received teriflunomide for 14 days, followed by an AEP with colestipol HCl for 15 days. Results and Conclusions: The administration of colestipol HCl for 15 days was sufficient to reduce plasma teriflunomide concentrations by greater than 96%. Although colestipol HCl did not completely eliminate teriflunomide with the same effectiveness as cholestyramine, it may offer an alternative method for accelerated elimination of teriflunomide with potentially improved tolerability and more favorable dosing and administration options.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu